NOVAVAX INC NOVAVAX ORD SHS 

$11.9
835
-$2.75-18.8% Friday 18:12

统计数据

当日最高
14.7
当日最低
13.18
52周最高
27
52周最低
3.53
成交量
199,351
平均成交量
157,217
市值
-
市盈率
-
股息收益率
-
股息
-

即将到来

收益

6Nov预期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一个
-3.46
-1.75
-0.04
1.67
预期每股收益
-0.903333
实际每股收益
N/A

人们还关注

此列表基于关注0A3S.LSE的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。

关于

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Show more...
首席执行官
Mr. John Charles Jacobs M.B.A.
员工
1543
国家
US
ISIN
US6700024010

上市公司